Epstein-Barr virus (EBV) associated with several diseases such as contagious mononucleosis chronic active EBV infection, and diverse sorts of malignant tumors. Therefore, using applicable vaccines could be advantageous for public health. Yet, the vaccine has been unavailable to protect from EBV so far. In the current study, to develop a multi-peptide vaccine for EBV and assess its expression in yeast system, three immunodominant sequences in glycoprotein (gp) 85, gp350 and latent membrane protein 1 (LMP1) were chosen. To construct fusion peptide, -GGGGS- liker was applied. After cloning the fusion peptide in the pPICZαA expression vector, this recombinant vector processed and transfected into host cells. The expression of high level of EBV fusion peptide was confirmed by dot blot and SDS-PAGE procedures. The is capable of supporting EBV fusion peptide expression. The application of this fusion peptide as a peptide vaccine to fight EBV is suggested.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8530268PMC
http://dx.doi.org/10.1080/21655979.2019.1694388DOI Listing

Publication Analysis

Top Keywords

fusion peptide
20
ebv fusion
8
peptide
7
ebv
7
fusion
5
construction epstein-bar
4
epstein-bar virus
4
virus cocktail
4
cocktail peptide
4
peptide fused
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!